Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

BACKGROUND: NeoSphere showed significantly higher pathologic complete response (pCR) with neoadjuvant pertuzumab, trastuzumab, and docetaxel compared with trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel. We assessed associations between human epidermal growth fa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res
Main Authors: Bianchini, Giampaolo, Kiermaier, Astrid, Bianchi, Giulia Valeria, Im, Young-Hyuck, Pienkowski, Tadeusz, Liu, Mei-Ching, Tseng, Ling-Ming, Dowsett, Mitch, Zabaglo, Lila, Kirk, Sarah, Szado, Tania, Eng-Wong, Jennifer, Amler, Lukas C., Valagussa, Pinuccia, Gianni, Luca
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5299741/
https://ncbi.nlm.nih.gov/pubmed/28183321
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-017-0806-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados